Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 0.96%.

  • Harvard Bioscience's EBITDA Margin rose 94900.0% to 0.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.55%, marking a year-over-year decrease of 514700.0%. This contributed to the annual value of 6.6% for FY2024, which is 82900.0% down from last year.
  • Per Harvard Bioscience's latest filing, its EBITDA Margin stood at 0.96% for Q3 2025, which was up 94900.0% from 4.0% recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's EBITDA Margin peaked at 13.69% during Q2 2022, and registered a low of 228.11% during Q1 2025.
  • In the last 5 years, Harvard Bioscience's EBITDA Margin had a median value of 0.89% in 2021 and averaged 14.26%.
  • In the last 5 years, Harvard Bioscience's EBITDA Margin soared by 291600bps in 2023 and then crashed by -2188100bps in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's EBITDA Margin stood at 5.14% in 2021, then plummeted by -131bps to 1.61% in 2022, then surged by 162bps to 1.0% in 2023, then tumbled by -96bps to 0.04% in 2024, then surged by 2036bps to 0.96% in 2025.
  • Its EBITDA Margin was 0.96% in Q3 2025, compared to 4.0% in Q2 2025 and 228.11% in Q1 2025.